临床外科杂志 ›› 2021, Vol. 29 ›› Issue (3): 265-268.doi: 10.3969/j.issn.1005-6483.2021.03.018

• • 上一篇    下一篇

混合核苷片预防乳腺癌表柔比星+环磷酰胺方案辅助化疗所致骨髓抑制的临床研究

  

  1. 637000 四川南充,川北医学院附属医院甲状腺乳腺外科(李金穗、蒲卢兰、徐明飞、侯令密、高砚春);川北医学院第二临床医学院/南充市中心医院手术室(周瑶)
  • 出版日期:2021-03-20 发布日期:2021-03-20
  • 通讯作者: 高砚春,Email:boyang111@163.com

Clinical study on the prevention of bone marrow suppression induced by AC chemotherapy with mixed nucleoside tablets of breast cancer patients

  1. Department of Breast Surgery,Affiliated Hospital of North Sichuan Medical College,Sichuan,Nanchong,637000, China
  • Online:2021-03-20 Published:2021-03-20

摘要: 目的  探讨乳腺癌病人表柔比星+环磷酰胺(AC)方案辅助化疗期间,使用混合核苷片预防骨髓抑制的临床效果。
方法  2018年1月~2019年12月我院行手术治疗后的乳腺癌病人84例,均使用AC(21天)方案行辅助化疗。将84例病人随机分为治疗组和对照组,每组各42例。对照组在AC方案化疗过程中若出现Ⅱ度及以上骨髓抑制,采用重组人粒细胞集落刺激因子注射液(recombinant human colony-stimulating factor,rh G-CSF)5μg/kg皮下注射。治疗组加用混合核苷片每次40mg,每天3次。化疗开始后每周期d7、d9、d11进行血常规检查,分析两组病人放化疗期间血小板、白细胞和中性粒细胞计数变化情况、骨髓抑制程度、骨髓抑制出现时间及中性粒细胞减少症(febrile neutropenia,FN)出现次数。
结果  治疗前,两组病人血小板、白细胞、中性粒细胞比较差异无统计学意义(P>0.05),化疗结束后,两组血小板、白细胞、中性粒细胞计数均有不同程度地下降,差异有统计学意义(P<0.05)。与对照组比较,治疗组不同周期血小板、白细胞、中性粒细胞计数均有不同程度地增高。两组治疗后均有骨髓抑制出现,其中治疗组≥Ⅱ度骨髓抑制发生率为 6.55%,对照组为 13.10%,治疗组低于对照组,差异有统计学意义(P<0.05)。治疗组平均出现骨髓抑制反应时间晚于对照组[(9.8±1.1)天和(7.5±1.4)天,t=8.372,P=0.000)]。治疗组总共出现FN 2人/次,对照组总共出现FN 9人/次,治疗组出现FN次数较对照组少,差异有统计学意义(P<0.05)。
结论  混合核苷片可有效改善乳腺癌AC方案辅助化疗病人的骨髓抑制情况,减少FN的发生。在低危风险的乳腺癌AC方案中使用混合核苷片可能成为FN低风险化疗方案的新选择。

关键词: 混合核苷片, 乳腺癌, 辅助化疗, 骨髓抑制

Abstract: Objective  To investigate the clinical effect of using mixed nucleoside tablets to prevent bone marrow suppression during AC adjuvant chemotherapy for breast cancer.
Methods  A total of 84 cases breast cancer patients who had received surgical treatment in our hospital from January 2018 to December 2019 were selected and all received adjuvant chemotherapy using AC regimen(21 days).The patients were randomly divided into the treatment group(42 patients) and the control group(42 patients).In the control group,if degree Ⅱ or above bone marrow suppression occurred during chemotherapy,recombinant human granulocyte colony stimulating factor injection(rh G-CSF) 5g/kg was administered subcutaneously.In the treatment group,mixed nucleoside tablets of 40mg/time were given orally,3 times/d,during chemotherapy.The blood routine examination was conducted on the 7th,9th and 11th day during 4 periods of chemotherapy.Changes of platelet,white blood cell and neutrophil count,degree of bone marrow suppression,occurrence time of bone marrow suppression and occurrence times of FN were compared and analyzed between 2 groups.
Results  Before treatment,there was no significant difference in the platelets,white blood cells and neutrophils between 2 groups(P>0.05).After chemotherapy,the counts of platelets,white blood cells and neutrophils of 2 groups decreased(P<0.05) Compared with the control group,the counts of platelets,white blood cells,and neutrophils in the treatment group increased to varying degrees in 4 periods of chemotherapy.Bone marrow suppression occurred in both groups after chemotherapy.The incidence of bone marrow suppression in the treatment group was 6.55%,and the control group was 13.10%.The incidence of bone marrow suppression in the treatment group was lower than the control group(P<0.05).The average response time of bone marrow suppression in the treatment group was later than that in the control group [(9.8±1.1)d vs.(7.5±1.4)d,t=8.372,P=0.000)].There were 2 people/period of FN in the treatment group,9 people/period in the control group,and fewer FNs in the treatment group than in the control group(P<0.05).
Conclusion  The mixed nucleoside tablets can effectively improve the myelosuppression of breast cancer patients with AC adjuvant chemotherapy and reduce the occurrence of FN.The use of mixed nucleoside tablets in AC adjuvant chemotherapy for low-risk breast cancer may become a new choice for FN low-risk adjuvant chemotherapy.

Key words: mixed nucleoside tablets, breast cancer, adjuvant chemotherapy, bone marrow suppression

[1] 蔡耿喜 刘强. 乳腺癌的精准治疗[J]. 临床外科杂志, 2021, 29(3): 201-207.
[2] 刘健 吴凡. 精准医学对乳腺癌化疗方案选择的积极意义[J]. 临床外科杂志, 2021, 29(3): 208-211.
[3] 王朝斌 王殊. 乳腺癌保留腋窝的临床试验进展[J]. 临床外科杂志, 2021, 29(3): 212-214.
[4] 马天怡 王海波. 肿瘤整形技术在保乳手术中的应用与进展[J]. 临床外科杂志, 2021, 29(3): 215-217.
[5] 黄春旺 丛淑珍. 非典型乳腺癌超声诊断的要点及难点[J]. 临床外科杂志, 2021, 29(3): 218-221.
[6] 任敏 徐云凤. 乳腺癌乳房成形手术方法的精准选择[J]. 临床外科杂志, 2021, 29(3): 222-225.
[7] 戴嘉婧 韩馨乐 钟福波 林哲广 江淑琪 韦伟 方征宇. 三阴性乳腺癌与癌旁组织中差异表达环状RNA筛选及生物信息学分析[J]. 临床外科杂志, 2021, 29(3): 227-230.
[8] 杨丽 朱荔 刘紫朦 鲍宝石 马金平 王建东. 超声引导下空芯针穿刺活检对乳腺癌的诊断价值[J]. 临床外科杂志, 2021, 29(3): 231-234.
[9] 聂丽静 奚凯雯 韦嘉玲 董晓晶 方琼 金玉翡. 个案管理模式下乳腺癌病人辅助内分泌治疗依从性分析[J]. 临床外科杂志, 2021, 29(3): 235-238.
[10] 黄雅静 吴昊 罗智勇. 乳腺癌术后一步法与二步法重建乳房的临床效果分析[J]. 临床外科杂志, 2021, 29(3): 239-242.
[11] 张振伟 孙家和 张立功 钱军. 乳腺癌骨转移病人危险因素及预后因素分析[J]. 临床外科杂志, 2021, 29(3): 243-247.
[12] 周蓓 王婧 李仲洋. miR-597调控FOSL2抑制乳腺癌细胞增殖、迁移及侵袭的研究[J]. 临床外科杂志, 2021, 29(3): 248-252.
[13] 段书强 鲍方 刘振邦 王菲 高慧敏 开蕾. 趋化因子配体12/趋化因子受体4轴在三阴性乳腺癌组织中表达及与淋巴结转移关系[J]. 临床外科杂志, 2021, 29(3): 254-257.
[14] 闫军 周高晋. 乳腺癌外周血单核细胞自噬相关基因表达及其与肿瘤复发的关系[J]. 临床外科杂志, 2021, 29(3): 258-260.
[15] 李颖 董明华 张萌萌 孟芳 杨晓慧. 低频超声微泡增强紫杉醇诱导三阴性乳腺癌细胞自噬的作用及机制[J]. 临床外科杂志, 2021, 29(3): 261-264.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 胡军, 李绍员, 李包根, 罗俊峰. 腹腔镜阑尾切除术中阑尾根部结扎与Hem-o-lok夹闭的对比研究[J]. 临床外科杂志, 2018, 26(12): 920 -921 .
[2] 李东航, 姚颐, 耿庆. 中国临床肿瘤学会肺癌诊疗指南(2018版)更新解读[J]. 临床外科杂志, 2019, 27(1): 36 -39 .
[3] 彭伟, 魏世平, 李辉明, 陶维雄, 顾鹏. 输尿管镜联合封堵器治疗输尿管上段结石失败原因的分析及对策[J]. 临床外科杂志, 2019, 27(2): 116 -117 .
[4] 唐云德, 徐卫国, 于风珍, 尚林强. 椎间孔镜微创技术治疗老年腰椎间盘突出症的临床分析[J]. 临床外科杂志, 2019, 27(5): 439 -442 .
[5] 朱栋良, 严海东, 黎尉浩, 尹小平. 异鼠李素对结肠癌细胞衰老的影响[J]. 临床外科杂志, 2019, 27(8): 684 -687 .
[6] 钱永尚, 余铃, 杨东风, 肖松, 李建东, 程晓锋. 微创经皮钢板接骨术与传统开放手术用于治疗肱骨近端骨折的临床疗效分析[J]. 临床外科杂志, 2019, 27(10): 904 -906 .
[7] 王嵩, 谢于峰, 颜大亮, 袁茂昆. 右心室罕见黏液瘤一例[J]. 临床外科杂志, 2019, 27(10): 922 .
[8] 王玉龙. 股骨近端防旋髓内钉与解剖型锁定钢板治疗老年股骨粗隆间骨折的疗效对比分析[J]. 临床外科杂志, 2019, 27(11): 977 -980 .
[9] 鲁林源, 曹永清, 张强, 卢丹, 赵向东. 视频辅助治疗手术对复杂性肛瘘病人症状及预后的影响[J]. 临床外科杂志, 2019, 27(12): 1041 -1043 .
[10] 付洋, 孔垂泽. 组蛋白去乙酰化酶9表达与恶性肿瘤预后相关性的Meta分析[J]. 临床外科杂志, 2020, 28(1): 87 -90 .